Ftse Mib
32.665,21
-2,81%
DAX
18.002,02
-1,43%
S&P 500
5.431,60
-0,04%
NASDAQ
17.688,88
0,12%
Bitcoin
66.452,77
0,39%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Silo Pharma Inc (SILO) Silo Pharma Inc (SILO) Notizie

SILO

Silo Pharma (SILO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SILO
DataOraFonteTitoloSimboloCompagnia
13/06/202423:08Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:SILOSilo Pharma Inc
13/06/202419:19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SILOSilo Pharma Inc
11/06/202422:00Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SILOSilo Pharma Inc
07/06/202414:18GlobeNewswire Inc.Silo Pharma Announces Successful Production of its SP-26 Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
06/06/202422:52Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SILOSilo Pharma Inc
06/06/202422:50GlobeNewswire Inc.Silo Pharma Announces Closing of $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
06/06/202412:07Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SILOSilo Pharma Inc
05/06/202414:00GlobeNewswire Inc.Silo Pharma Announces $2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesNASDAQ:SILOSilo Pharma Inc
04/06/202414:41GlobeNewswire Inc.Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and AnxietyNASDAQ:SILOSilo Pharma Inc
21/05/202414:45GlobeNewswire Inc.Silo Pharma Announces Positive Results from Study for Depression Treatment, Remission, and Relapse PreventionNASDAQ:SILOSilo Pharma Inc
14/05/202414:45GlobeNewswire Inc.Silo Pharma to Participate in FDA Meeting Exploring Emerging Therapeutic Interest in KetamineNASDAQ:SILOSilo Pharma Inc
13/05/202422:05Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SILOSilo Pharma Inc
23/04/202414:15GlobeNewswire Inc.Silo Pharma Announces Positive Results for Intranasal PTSD TreatmentNASDAQ:SILOSilo Pharma Inc
10/04/202414:11GlobeNewswire Inc.Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease TherapeuticNASDAQ:SILOSilo Pharma Inc
20/03/202413:30GlobeNewswire Inc.Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety TherapeuticNASDAQ:SILOSilo Pharma Inc
18/03/202412:15GlobeNewswire Inc.Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic PainNASDAQ:SILOSilo Pharma Inc
28/02/202414:25GlobeNewswire Inc.Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSDNASDAQ:SILOSilo Pharma Inc
14/02/202414:45GlobeNewswire Inc.Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug DeliveryNASDAQ:SILOSilo Pharma Inc
01/02/202416:00GlobeNewswire Inc.Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and NeurologyNASDAQ:SILOSilo Pharma Inc
31/01/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SILOSilo Pharma Inc
25/01/202423:29Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:SILOSilo Pharma Inc
25/01/202423:27Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SILOSilo Pharma Inc
24/01/202414:55GlobeNewswire Inc.Silo Pharma Announces Positive Results in Alzheimer’s Disease StudyNASDAQ:SILOSilo Pharma Inc
23/01/202423:01Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:SILOSilo Pharma Inc
11/01/202418:15Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SILOSilo Pharma Inc
04/01/202414:55GlobeNewswire Inc.Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
28/12/202314:25GlobeNewswire Inc.Silo Pharma and Partner Receive Regulatory Approval to Begin Development of Ketamine Implant for FibromyalgiaNASDAQ:SILOSilo Pharma Inc
20/12/202322:58Edgar (US Regulatory)Form 8-K12B - Notification that a class of securities of successor issuer is deemed to be registered pursuant to section 12(b)NASDAQ:SILOSilo Pharma Inc
21/11/202314:01GlobeNewswire Inc.Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSDNASDAQ:SILOSilo Pharma Inc
08/11/202314:11GlobeNewswire Inc.Silo Pharma to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSDNASDAQ:SILOSilo Pharma Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SILO

La tua Cronologia

BIT
UCG
Unicredit
BIT
ISP
Intesa Sanpaolo
BIT
STLAM
Stellantis NV
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
ENEL
Enel
BIT
ENI
Eni
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
STMMI
ST Microelectronics
BIT
BAMI
Banco BPM
BIT
RACE
Ferrari NV
BIT
SPM
Saipem
BIT
G
Generali
BIT
NEXI
Nexi S.p.A
BIT
TIT
Telecom Italia
BIT
PST
Poste Italiane S.p.a
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network